---
layout: default
title: Riluzole
description: "Riluzole çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚åˆæ­¥è­‰æ“šç­‰ç´š L4ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: ä¸­è­‰æ“šç­‰ç´š (L3-L4)
nav_order: 148
evidence_level: L4
indication_count: 10
---

# Riluzole

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L4</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Riluzoleï¼šå¾ ALS åˆ°é‹å‹•ç¥ç¶“å…ƒç›¸é—œç–¾ç—…

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Riluzole å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Riluzole æ˜¯ä¸€ç¨®è°·æ°¨é…¸æ‹®æŠ—åŠ‘ï¼ŒåŸæœ¬ç”¨æ–¼è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰çš„æ²»ç™‚ã€‚TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°å¤šç¨®é‹å‹•ç¥ç¶“å…ƒç›¸é—œç–¾ç—…æœ‰æ•ˆï¼ŒåŒ…æ‹¬**ä¸‹é‹å‹•ç¥ç¶“å…ƒç—‡å€™ç¾¤ (Lower Motor Neuron Syndrome)** å’Œ **ALS æ˜“æ„Ÿæ€§**ï¼Œç›®å‰æœ‰ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | bilateral parasagittal parieto-occipital polymicrogyriaã€amyotrophic lateral sclerosisã€axial spondylometaphyseal dysplasiaã€lower motor neuron syndrome with late-adult onsetã€trichomegaly-retina pigmentary degeneration-dwarfism syndromeã€lethal arthrogryposis-anterior horn cell disease syndromeã€monomelic amyotrophyã€Mills syndromeã€amyotrophic lateral sclerosis, susceptibility toã€autosomal dominant mitochondrial myopathy with exercise intolerance |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.94%-99.98% |
| è­‰æ“šç­‰ç´š | L4 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed with Guardrails |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. bilateral parasagittal parieto-occipital polymicrogyria</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.99%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

Riluzole æ˜¯ç›®å‰å”¯ä¸€è¢«æ ¸å‡†ç”¨æ–¼ ALS æ²»ç™‚çš„è—¥ç‰©ã€‚å®ƒçš„ä¸»è¦ä½œç”¨æ©Ÿè½‰åŒ…æ‹¬ï¼š
- æŠ‘åˆ¶è°·æ°¨é…¸é‡‹æ”¾
- é˜»æ–·é›»å£“ä¾è³´æ€§éˆ‰é›¢å­é€šé“
- æ¸›å°‘èˆˆå¥®æ€§æ¯’æ€§ï¼ˆexcitotoxicityï¼‰

ALS çš„ç‰¹å¾µæ˜¯ä¸Šä¸‹é‹å‹•ç¥ç¶“å…ƒçš„é€²è¡Œæ€§é€€åŒ–ã€‚TxGNN é æ¸¬çš„å¹¾å€‹é©æ‡‰ç—‡èˆ‡ ALS åœ¨ç—…ç†æ©Ÿè½‰ä¸Šæœ‰å¯†åˆ‡é—œè¯ï¼š

1. **ä¸‹é‹å‹•ç¥ç¶“å…ƒç—‡å€™ç¾¤ï¼ˆæ™šç™¼å‹ï¼‰**ï¼šèˆ‡ ALS å…±äº«ä¸‹é‹å‹•ç¥ç¶“å…ƒé€€åŒ–çš„ç‰¹å¾µ
2. **Mills ç—‡å€™ç¾¤**ï¼šä¸€ç¨®ä»¥å–®å´é€²è¡Œæ€§è‚¢é«”ç„¡åŠ›ç‚ºç‰¹å¾µçš„é‹å‹•ç¥ç¶“å…ƒç–¾ç—…
3. **ALS æ˜“æ„Ÿæ€§**ï¼šä»£è¡¨å¯èƒ½ç™¼å±•ç‚º ALS çš„é«˜é¢¨éšªç‹€æ…‹
4. **å–®è‚¢è‚Œèç¸®ç—‡ï¼ˆMonomelic Amyotrophyï¼‰**ï¼šä¸€ç¨®å±€é™æ€§çš„é‹å‹•ç¥ç¶“å…ƒç–¾ç—…

é€™äº›ç–¾ç—…éƒ½æ¶‰åŠé‹å‹•ç¥ç¶“å…ƒçš„é€€åŒ–ï¼Œriluzole çš„ç¥ç¶“ä¿è­·ä½œç”¨å¯èƒ½å°é€™äº›ç–¾ç—…æœ‰é¡ä¼¼çš„ç™‚æ•ˆã€‚

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡é‡å°é€™äº›ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—ç™»è¨˜ã€‚

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [9178165](https://pubmed.ncbi.nlm.nih.gov/9178165/) | 1997 | Review | J Neurol | è°·æ°¨é…¸ã€èˆˆå¥®æ€§æ¯’æ€§èˆ‡ ALS çš„é—œä¿‚ï¼Œriluzole ä½œç‚ºæ²»ç™‚é¸æ“‡ |
| [16723044](https://pubmed.ncbi.nlm.nih.gov/16723044/) | 2006 | Review | Expert Rev Mol Med | ALS çš„ç—…ç†æ©Ÿè½‰å’Œæ²»ç™‚é€”å¾‘ï¼Œriluzole æ˜¯å”¯ä¸€å»¶é•·å­˜æ´»çš„è—¥ç‰© |
| [21128691](https://pubmed.ncbi.nlm.nih.gov/21128691/) | 2011 | Review | CNS Drugs | ALS çš„ç—…ç†ç”Ÿç†å­¸ã€è¨ºæ–·å’Œæ²»ç™‚ç®¡ç† |
| [20942786](https://pubmed.ncbi.nlm.nih.gov/20942786/) | 2010 | Review | CNS Neurol Disord Drug Targets | ALS çš„è¨ºæ–·ã€ç™¼ç—…æ©Ÿåˆ¶å’Œæ²»ç™‚æ¨™é¶ |
| [19593125](https://pubmed.ncbi.nlm.nih.gov/19593125/) | 2009 | Review | Curr Opin Neurol | é‹å‹•ç¥ç¶“å…ƒç–¾ç—…çš„æœ€æ–°é€²å±• |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. axial spondylometaphyseal dysplasia</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. lower motor neuron syndrome with late-adult onset</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. trichomegaly-retina pigmentary degeneration-dwarfism syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. lethal arthrogryposis-anterior horn cell disease syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. monomelic amyotrophy</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.99%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.99%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. Mills syndrome</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. amyotrophic lateral sclerosis, susceptibility to</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. autosomal dominant mitochondrial myopathy with exercise intolerance</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. amyotrohpic lateral sclerosis type 22</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.98%</span>
</summary>
<div class="indication-content">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.98%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬XXXXXXè™Ÿ | ç‰¹é­¯å¸Œå£æœæ‡¸æµ®æ¶² 5æ¯«å…‹/æ¯«å‡ | å£æœæ‡¸æµ®æ¶² | è‚Œèç¸®è„Šé«“å´ç´¢ç¡¬åŒ–ç—‡ï¼ˆALSï¼‰ |

## å®‰å…¨æ€§è€ƒé‡

**ä¸»è¦è­¦èªï¼š**
- è‚æ¯’æ€§ï¼šéœ€å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- é–“è³ªæ€§è‚ºç—…ï¼šç½•è¦‹ä½†åš´é‡

**ç¦å¿Œç—‡ï¼š**
- åš´é‡è‚åŠŸèƒ½æå®³

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**å’–å•¡å› ï¼ˆå’–å•¡ã€èŒ¶ã€å¯æ¨‚ï¼‰** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå’–å•¡å› å¯èƒ½èˆ‡ Riluzole ç«¶çˆ­ä»£è¬
- å»ºè­°ï¼šé©é‡æ”å–å’–å•¡å› 



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Alcoholism** ğŸŸ¡ Moderate
- Alcohol consumption may intensify the hepatotoxic potential of riluzole.  Therefore, patients should be warned to limit alcohol intake while receiving riluzole therapy.

**è‚è‡Ÿç–¾ç—… (Liver Diseases)** ğŸŸ¡ Moderate
- The use of riluzole has been frequently associated with an increase in liver enzymes between 3 and 5 times the upper limit of normal (ULN).  Therapy with riluzole should be administered cautiously in patients with a history of liver dysfunction.  Bas...

**Neutropenia** ğŸŸ¡ Moderate
- The use of riluzole has rarely been associated with neutropenia with an absolute neutrophil count (ANC) less than 500/mm3.  The neutropenia developed within the first 2 months of treatment.  Therapy with riluzole should be administered cautiously in ...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- Riluzole and its metabolites are eliminated via the kidney.  Therapy with riluzole should be administered cautiously in patients with renal dysfunction.  Reduced clearance and higher plasma levels may occur in these patients.  Women, native Japanese ...

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed with Guardrails**

**ç†ç”±ï¼š**
TxGNN é æ¸¬çš„é©æ‡‰ç—‡èˆ‡ ALS åœ¨ç—…ç†æ©Ÿè½‰ä¸Šé«˜åº¦ç›¸é—œï¼Œéƒ½æ¶‰åŠé‹å‹•ç¥ç¶“å…ƒçš„é€€åŒ–ã€‚Riluzole çš„ç¥ç¶“ä¿è­·ä½œç”¨æ©Ÿè½‰ï¼ˆæŠ—è°·æ°¨é…¸æ¯’æ€§ï¼‰åœ¨ç†è«–ä¸Šå¯èƒ½å°é€™äº›ç–¾ç—…æœ‰æ•ˆã€‚ç„¶è€Œï¼Œç”±æ–¼ç¼ºä¹é‡å°é€™äº›ç‰¹å®šé©æ‡‰ç—‡çš„è‡¨åºŠè©¦é©—æ•¸æ“šï¼Œéœ€è¦è¬¹æ…è©•ä¼°ã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- å° Mills ç—‡å€™ç¾¤ã€å–®è‚¢è‚Œèç¸®ç—‡ç­‰é‹å‹•ç¥ç¶“å…ƒç–¾ç—…é€²è¡Œå°è¦æ¨¡è‡¨åºŠç ”ç©¶
- æ”¶é›†çœŸå¯¦ä¸–ç•Œè­‰æ“šï¼ˆå¦‚ ALS é–€è¨ºä¸­å…¶ä»–é‹å‹•ç¥ç¶“å…ƒç–¾ç—…æ‚£è€…ä½¿ç”¨ riluzole çš„ç¶“é©—ï¼‰
- å®šæœŸç›£æ¸¬è‚åŠŸèƒ½
- è©•ä¼°é•·æœŸç™‚æ•ˆå’Œå®‰å…¨æ€§


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cisatracurium]({{ "/drugs/cisatracurium/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Pralatrexate]({{ "/drugs/pralatrexate/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Minoxidil]({{ "/drugs/minoxidil/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Dl-Alpha-Tocopherol]({{ "/drugs/dl-alpha-tocopherol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4
- [Acebutolol]({{ "/drugs/acebutolol/" | relative_url }}) - è­‰æ“šç­‰ç´š L4

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Riluzoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/riluzole/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_riluzole,
  title = {Riluzoleè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/riluzole/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
